SGLT2 INHIBITORS: EFFECTS ON CARDIOPROTECTION - Boukheloua, Mourad;CHELGHOUM, SOUAD;GACEM, OURIDA
44,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as anti-hyperglycemic drugs, have been shown to significantly improve metabolic indicators and protect the kidneys and hearts of patients with and without type 2 diabetes. The possible mechanisms for these benefits are the subject of extensive research, as they cannot be attributed solely to improved blood sugar control. In this book, we will focus on the current understanding of cardio-renal protection by SGLT2 inhibitors by explaining the pathophysiological mechanisms involved, and we will present the largest trials that have demonstrated this organoprotective effect.…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, initially developed as anti-hyperglycemic drugs, have been shown to significantly improve metabolic indicators and protect the kidneys and hearts of patients with and without type 2 diabetes. The possible mechanisms for these benefits are the subject of extensive research, as they cannot be attributed solely to improved blood sugar control. In this book, we will focus on the current understanding of cardio-renal protection by SGLT2 inhibitors by explaining the pathophysiological mechanisms involved, and we will present the largest trials that have demonstrated this organoprotective effect.
Autorenporträt
Mourad BOUKHELOUA, Maitre de Conférences à la faculté de médecine d'Alger and chef d'unité de cardiologie interventionnelle au CHU Hussein Dey, auteur de plusieurs ouvrages.Souad CHELGHOUM, Professor of néphrologie, transplantation et Plasmaphérèses, CHU Hussein Dey.Ourida GACEM, professor and expert in pediatric rhumatology at the BIRTRARIA hospital.